Buparlisib (BKM120), another pan-PI3K inhibitor, exhibited limited antitumor activity in patients with HNSCC, with a disease control rate of 49% and an ORR of only 3% (NCT01527877; NCT01737450) (85, 130). This evidence concerns the gene PIK3CA and head and neck squamous cell carcinoma.